Loading people...
Chau Khuong is the Founder and Chief Investment Officer of CJNV BioVentures and a General Partner at Catalio Capital Management, based in New York. Prior to establishing his own firm in 2021, he spent nearly two decades as a Partner at OrbiMed Advisors, directing venture capital deployment for the healthcare investment firm with $15 billion in assets under management. Over his 25-year career, he has led investments in more than two dozen life science companies, contributing to the development of 12 FDA-approved medicines and therapeutic devices. His portfolio includes significant exits such as Synthorx, acquired by Sanofi for $2.5 billion, and Bellus Health, purchased by GSK for $2 billion. He previously conducted research at Massachusetts General Hospital and holds dual degrees from Yale University. Khuong currently focuses on providing capital solutions to early-stage and mature biotechnology enterprises.
Chau Khuong stands as a prominent Partner at OrbiMed, a globally recognized investment firm singularly focused on the dynamic healthcare industry. Since joining OrbiMed in 2003, Mr. Khuong has played a pivotal role in the firm's private equity and venture capital strategies, contributing significantly to its reputation as a leader in healthcare investment.
At OrbiMed, Chau Khuong's primary responsibilities involve identifying, evaluating, and executing private equity investments. His investment focus is broad yet deeply specialized within healthcare, encompassing a wide array of sub-sectors. These include groundbreaking biopharmaceutical companies developing novel therapeutics, innovative medical device manufacturers, advanced diagnostics firms, and essential healthcare services providers. He is adept at navigating the complexities of both early-stage ventures and more mature growth-stage companies, consistently seeking opportunities that promise significant impact and returns within the healthcare ecosystem.
Mr. Khuong's career background is marked by a strong foundation in both business and healthcare strategy. Prior to his tenure at OrbiMed, he honed his analytical and strategic skills at McKinsey & Company. During his time as a consultant, he provided invaluable guidance to pharmaceutical and biotechnology companies, advising them on critical strategic and operational challenges. This experience equipped him with a deep understanding of the industry's intricacies, from drug development pipelines to market access strategies, which he now leverages in his investment decisions at OrbiMed. Academically, Chau Khuong holds an MBA from Harvard Business School and a BA from Harvard University, underscoring his robust educational foundation.
Throughout his career at OrbiMed, Chau Khuong has been instrumental in numerous successful investments, often serving on the boards of directors for various portfolio companies. While specific individual investments are typically confidential, his work aligns with OrbiMed's broader strategy of backing companies that are poised to deliver transformative healthcare solutions. His involvement helps guide these companies through critical growth phases, from clinical development and regulatory hurdles to commercialization and market expansion. His strategic insights and extensive network within the healthcare and financial communities make him a highly valued partner to the companies OrbiMed invests in, driving innovation and fostering growth across the global healthcare landscape.
Chau Khuong is a Partner at OrbiMed, a leading global investment firm exclusively focused on the healthcare sector. He specializes in private equity and venture capital investments.
Chau Khuong invests in a diverse range of healthcare companies, including those in biopharmaceuticals, medical devices, diagnostics, and healthcare services. His focus spans both early-stage and growth-stage private equity opportunities.
Chau Khuong works as a Partner at OrbiMed, a prominent investment firm dedicated to the healthcare industry. He joined OrbiMed in 2003.
